Yorkshire Collaborative Small Cell Lung Cancer Study
| ISRCTN | ISRCTN15654915 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15654915 |
| Protocol serial number | TH/SMC |
| Sponsor | Northern and Yorkshire Clinical Trials and Research Unit (UK) |
| Funder | Northern & Yorkshire Clinical Trials & Research Unit (UK) |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 24/10/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | Yorkshire Collaborative Small Cell Lung Cancer Study |
| Study objectives | Not provided at time of registration |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Lung (small cell) |
| Intervention | Good/moderate-prognosis patients: Patients receive chemotherapy with Ifosfamide, etoposide, mensa and vincristine (EIMV) for three courses. Patients with greater than 50% response are randomised to either: 1. Group A: No mandatory treatment, radiotherapy is optional. 2. Group B: Three further courses of EIMV chemotherapy plus optional radiotherapy. Poor-prognosis patients: Chemotherapy is at the physicians discretion. If chemotherapy is chosen single agent etoposide or EIMV chemotherapy is recommended. |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/04/1995 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Key inclusion criteria | 1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology. 2. Aged <75 years 3. Normal renal and hepatic function 4. No evidence of brain metastases 5. No previous specific anti-cancer treatment for current disease 6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/01/1994 |
| Date of final enrolment | 01/04/1995 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
24/10/2019: No publications found. All search options exhausted.
